Litcius/Paper detail

Is teicoplanin a complementary treatment option for COVID-19? The question remains

Giancarlo Ceccarelli, Francesco Alessandri, Gabriella d’Ettorre, Cristian Borrazzo, Ornella Spagnolello, Alessandra Oliva, Franco Ruberto, Claudio Maria Mastroianni, Francesco Pugliese, Mario Venditti

2020International Journal of Antimicrobial Agents52 citationsDOIOpen Access PDF

Topics & Concepts

Coronavirus disease 2019 (COVID-19)Teicoplanin2019-20 coronavirus outbreakSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)MedicineIntensive care medicineVirologyInternal medicineVancomycinInfectious disease (medical specialty)BiologyDiseaseStaphylococcus aureusGeneticsBacteriaOutbreakCOVID-19 Clinical Research StudiesSARS-CoV-2 and COVID-19 ResearchLong-Term Effects of COVID-19
Is teicoplanin a complementary treatment option for COVID-19? The question remains | Litcius